Budesonide - a new steroid for intranasal use. A double-blind clinical comparison between budesonide and placebo in patients with seasonal allergic rhinitis.
Twenty-nine patients with seasonal rhinitis completed a double-blind study comparing budesonide nasal spray 200 micrograms b.i.d. with placebo. The patients were randomly assigned into two parallel groups. Symptoms were assessed over a treatment period of 3 weeks. There were statistically significant differences in favour of budesonide on all measurements. Side effects were mild and the incidence was low.